University of Alabama at Birmingham, Heersink School of Medicine, Department of Emergency Medicine, Birmingham, Alabama.
Birmingham VA Medical Center, Department of Emergency Medicine, Birmingham, Alabama.
West J Emerg Med. 2023 Nov;24(6):1010-1017. doi: 10.5811/westjem.60511.
Recent studies have demonstrated the promise of emergency department (ED)-initiated buprenorphine/naloxone (bup/nx) for improving 30-day retention in outpatient addiction care programs for patients with opioid use disorder (OUD). We investigated whether ED-initiated bup/nx for OUD also impacts repeat ED utilization.
We performed a retrospective chart review of ED patients discharged with a primary diagnosis of OUD from July 2019-December 2020. Characteristics considered included age, gender, race, insurance status, domicile status, presence of comorbid Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis, presenting chief complaint, and provision of a bup/nx prescription and/or naloxone kit. Primary outcomes included repeat ED visit (opioid or non-opioid related) within 30 days, 90 days, and one year. Statistical analyses included bivariate comparison and Poisson regression.
Of 169 participants, the majority were male (67.5%), White (82.8%), uninsured (72.2%), and in opioid withdrawal and/or requesting "detox" (75.7%). Ninety-one (53.8%) received ED-initiated bup/nx, which was independent of age, gender, race, insurance status, presence of comorbid DSM-5 diagnosis, or domicile status. Naloxone was more likely to be provided to patients who received bup/nx (97.8% vs 26.9%; < 0.001), and bup/nx was more likely to be given to patients who presented with opioid withdrawal and/or requested "detox" (63.3% vs 36.7%; < 0.001). Bup/nx provision was associated with decreased ED utilization for opioid-related visits at 30 days ( = 0.04). Homelessness and lack of insurance were associated with increased ED utilization for non-opioid-related visits at 90 days ( = 0.008 and = 0.005, respectively), and again at one year for homelessness ( < 0.001). When controlling for age and domicile status, the adjusted incidence rate ratio for overall ED visits was 0.56 (95% confidence interval [CI] 0.33-0.96) at 30 days, 0.43 (95% CI 0.27-0.69) at 90 days, and 0.60 (95% CI 0.39-0.92) at one year, favoring bup/nx provision.
Initiation of bup/nx in the ED setting was associated with decreased subsequent ED utilization. Socioeconomic factors, specifically health insurance and domicile status, significantly impacted non-opioid-related ED reuse. These findings demonstrate the ED's potential as an initiation point for bup/nx and highlight the importance of considering the social risk and social need for OUD patients.
最近的研究表明,急诊科(ED)启动的丁丙诺啡/纳洛酮(丁丙诺啡/纳洛酮)有望改善阿片类药物使用障碍(OUD)患者在门诊成瘾护理项目中的 30 天保留率。我们调查了 OUD 的 ED 启动丁丙诺啡/纳洛酮是否也会影响重复 ED 使用。
我们对 2019 年 7 月至 2020 年 12 月期间从急诊科出院的原发性 OUD 患者进行了回顾性图表审查。考虑的特征包括年龄、性别、种族、保险状况、户籍状况、是否存在合并的诊断和统计手册,第五版(DSM-5)诊断、主要主诉以及提供丁丙诺啡/纳洛酮处方和/或纳洛酮套件。主要结果包括 30 天、90 天和 1 年内重复 ED 就诊(阿片类或非阿片类相关)。统计分析包括双变量比较和泊松回归。
在 169 名参与者中,大多数为男性(67.5%)、白人(82.8%)、无保险(72.2%)、阿片类药物戒断和/或要求“戒毒”(75.7%)。91 人(53.8%)接受了 ED 启动的丁丙诺啡/纳洛酮,这与年龄、性别、种族、保险状况、是否存在合并的 DSM-5 诊断或户籍状况无关。接受丁丙诺啡/纳洛酮的患者更有可能接受纳洛酮(97.8%比 26.9%;<0.001),而接受丁丙诺啡/纳洛酮的患者更有可能出现阿片类药物戒断和/或要求“戒毒”(63.3%比 36.7%;<0.001)。丁丙诺啡/纳洛酮的提供与 30 天内阿片类药物相关就诊的 ED 利用率降低有关(=0.04)。无家可归和缺乏保险与 90 天内非阿片类相关就诊的 ED 利用率增加有关(分别为=0.008 和=0.005),再次在一年中与无家可归有关(<0.001)。在控制年龄和户籍状况后,30 天时总体 ED 就诊的调整发病率比为 0.56(95%置信区间 [CI] 0.33-0.96),90 天时为 0.43(95% CI 0.27-0.69),1 年时为 0.60(95% CI 0.39-0.92),丁丙诺啡/纳洛酮的使用更为有利。
ED 环境中丁丙诺啡/纳洛酮的启动与随后 ED 利用率的降低有关。社会经济因素,特别是医疗保险和户籍状况,对非阿片类相关 ED 再利用有显著影响。这些发现表明 ED 有可能成为丁丙诺啡/纳洛酮的起始点,并强调了考虑 OUD 患者的社会风险和社会需求的重要性。